<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04796441</url>
  </required_header>
  <id_info>
    <org_study_id>CAR-γδT cell for AML</org_study_id>
    <nct_id>NCT04796441</nct_id>
  </id_info>
  <brief_title>Clinical Study of Universal CAR-γδT Cell Injection in the Treatment of Patients With Relapsed AML After Transplantation</brief_title>
  <official_title>Clinical Study of Universal CAR-γδT Cell Injection in the Treatment of Patients With Relapsed AML After Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hebei Senlang Biotechnology Inc., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hebei Senlang Biotechnology Inc., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open single-arm clinical study aimed at evaluating the efficacy and safety of&#xD;
      universal γδT cell injection in the treatment of patients with relapsed AML after&#xD;
      transplantation&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Main purpose: To evaluate the safety and effectiveness of universal CAR-γδT cell injection in&#xD;
      the treatment of patients with relapsed AML after transplantation&#xD;
&#xD;
      Secondary purpose: to investigate the in vivo dynamics characteristics of universal CAR-γδT&#xD;
      cells after infusion and explore reasonable therapeutic doses through climbing tests in&#xD;
      different dose groups.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 16, 2020</start_date>
  <completion_date type="Anticipated">February 16, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 16, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety: Incidence and severity of adverse events</measure>
    <time_frame>First 1 month post CAR-T cells infusion</time_frame>
    <description>To evaluate the possible adverse events occurred within first one month after CAR-γδT infusion, including the incidence and severity of symptoms such as cytokine release syndrome and neurotoxicity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy: Remission Rate</measure>
    <time_frame>3 months post CAR-T cells infusion</time_frame>
    <description>Remission Rate including complete remission(CR)、CR with incomplete blood count recovery(CRi)、No remission(NR)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>duration of response (DOR)</measure>
    <time_frame>24 months post CAR-T cells infusion</time_frame>
    <description>duration of response (DOR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: progression-free survival (PFS)</measure>
    <time_frame>24 months post CAR-T cells infusion</time_frame>
    <description>progression-free survival (PFS) time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CAR-T proliferation</measure>
    <time_frame>3 months post CAR-T cells infusion</time_frame>
    <description>the copy number of CAR- γδT cells in the genomes of PBMC by qPCR method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytokine release</measure>
    <time_frame>First 1 month post CAR-T cells infusion</time_frame>
    <description>Cytokine( IL-6,IL-10,IFN-γ,TNF-α ) concentration (pg/mL) by flow cytometry method</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>AML</condition>
  <arm_group>
    <arm_group_label>CAR--γδT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be treated with CAR--γδT cells</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CAR-γδT</intervention_name>
    <description>Biological: CAR-γδT; Drug: Cyclophosphamide,Fludarabine; Procedure: Leukapheresis;</description>
    <arm_group_label>CAR--γδT</arm_group_label>
    <other_name>CD19 CAR-T</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with clinically diagnosed recurrence of AML after receiving transplant&#xD;
             therapy;&#xD;
&#xD;
          2. Flow cytometry (FCM) or immunohistochemical detection of tumor cells confirmed CD123&#xD;
             positive;&#xD;
&#xD;
          3. Age ≥2 years old and &lt;65 years old;&#xD;
&#xD;
          4. Survival is expected to be greater than 3 months from the date of signing of the&#xD;
             informed consent;&#xD;
&#xD;
          5. KPS 80 points or more;&#xD;
&#xD;
          6. The functions of vital organs shall meet the following conditions:&#xD;
&#xD;
        1) EF&gt;50%, and no obvious ECG abnormality; 2) SpO2 90% or more; 3) Cr 2.5 ULN or less; 4)&#xD;
        ALT And AST≤5ULN, TBil≤3ULN; 7. Subjects who plan to become pregnant must agree before&#xD;
        study enrollment and after study duration of 6 months Use contraception; Inform the&#xD;
        investigator immediately if the subject is pregnant or suspected to be pregnant; 8. Subject&#xD;
        or guardian understands and signs the informed consent;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Other diseases that have not been effectively controlled, including but not limited&#xD;
             to persistent or poorly controlled infections and diseases Congestive heart failure,&#xD;
             unstable angina pectoris, arrhythmias, poorly controlled lung disease Or mental&#xD;
             illness; 2. Other active malignant tumors; 3. Complicated with severe infection that&#xD;
             cannot be effectively controlled; 4. Active hepatitis B (HBVDNA) or HCV RNA [HCVRNA]&#xD;
             test was positive); 5. Human immunodeficiency virus (HIV) infection or syphilis&#xD;
             infection; 6. Have a history of severe allergy to biological products (including&#xD;
             antibiotics); 7. Acute graft-versus-host reaction (GVHD) was still present one month&#xD;
             after discontinuation of immunosuppressant therapy Allogeneic hematopoietic stem cell&#xD;
             transplantation patients; 8. Female subjects are in pregnancy and lactation; 9. Active&#xD;
             autoimmune diseases requiring systemic immunosuppression; 10. Conditions that the&#xD;
             investigator believes may increase the risk of the subject or interfere with the&#xD;
             results of the test;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peihua MD Lu, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hebei Yanda Ludaopei Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peihua MD Lu, PhD</last_name>
    <phone>008618611636172</phone>
    <email>peihua_lu@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jianqiang MD Li, PhD</last_name>
    <phone>008615511369555</phone>
    <email>limmune@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hebei yanda Ludaopei Hospital</name>
      <address>
        <city>Yanda</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peihua MD Lu, PhD</last_name>
      <phone>008618611636172</phone>
      <email>peihua_lu@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 8, 2021</study_first_submitted>
  <study_first_submitted_qc>March 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2021</study_first_posted>
  <last_update_submitted>March 11, 2021</last_update_submitted>
  <last_update_submitted_qc>March 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AML γδT CAR-</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

